Phase I/II Study of Plitidepsin (Aplidin) in Combination with Cytarabine in Patients with Relapsed/Refractory Leukemia.

Trial Profile

Phase I/II Study of Plitidepsin (Aplidin) in Combination with Cytarabine in Patients with Relapsed/Refractory Leukemia.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2014

At a glance

  • Drugs Plitidepsin (Primary) ; Cytarabine
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 18 Apr 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Oct 2008 New source identified and integrated (ClinicalTrials.gov record NCT00780143).
    • 31 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top